Got this challenging curbside consult from a colleague, and it has an interesting wrinkle.
In the latest treatment-naive trials of elvitegravir and dolutegravir, there's a striking consistency in the results of the "test" regimen. Here are the studies, with the percentage of responders by treatment arm ...
As has often been the case in the history of the HIV epidemic, the HIV/AIDS Division at San Francisco General Hospital and the San Francisco Department of Health were ahead of the curve in 2010 when they issued a recommendation that all people with HIV should receive treatment, regardless of CD4 count. Of course, U.S. guidelines (first DHHS, now IAS-USA) followed suit -- but how did the San Francisco experience play out?
Over in JAMA, there's a large study out today that (yet again) failed to demonstrate a benefit of vitamins.
Hard to believe, but we have to get rid of the HIV Western blot -- at least as our HIV confirmatory test.
We now have a third single-pill treatment available for HIV treatment, co-formulated tenofovir/emtricitabine/elvitegravir/cobicistat. From the FDA announcement:
The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection. Stribild contains two previously approved HIV drugs plus two new drugs, elvitegravir and cobicistat ... Together, these drugs provide a complete treatment regimen for HIV infection.
Todd sat slumped on the sofa in my office. He avoided eye contact and described a particularly painful experience with stigma. He had recently come around the corner at his part-time job and heard several co-workers speaking about him and his HIV positive status. More specifically, they were discussing how he might have acquired the virus by speculating about the nature and frequency of his sexual activities. It was meant as a cheap laugh among themselves, but for Todd it meant much more. Although he made no effort to hide his HIV status and was "out" at the office about being gay, hearing his co-workers making disparaging remarks about his sex life and his health status in such explicit terms felt like a strong punch in his gut. He had a brief flash of anger, telling them to shut up, and then stormed out, pulling inward and automatically falling into the old habit of numbing himself by detaching from the emotional pain.
The CDC issued its second "Interim Guidance" on the use of tenofovir/FTC as pre-exposure prophylaxis for prevention of HIV, this time for prevention of HIV in heterosexually active adults. The rationale?
Last week's International AIDS Conference in Washington got plenty of media attention, mostly because it was the first time in umpteen years that it was held in the United States, the delay between meetings due to our absurd (and now repealed) immigration laws regarding HIV.
As is typical of these meetings, which alternate with the smaller International AIDS Society Conference from year-to-year, there was plenty going on from a political and activist perspective. Still, there was some notable clinical research.
The early 1990s has potentially many associations -- the break-up of the Soviet Union, the first Gulf War, the World Trade Center and Oklahoma City bombings, The Lion King, Forest Gump, The Fresh Prince of Bel-Air, "Smells Like Teen Spirit," and the cancellation of the baseball season, to name a few.
But we HIV/ID specialists will always remember that period for something else -- namely, that deaths from AIDS in the United States peaked then, making it an especially challenging time to practice.